Literature DB >> 22451025

Relationship between sonographic parameters and YKL-40 levels in rheumatoid arthritis.

Maria Kazakova1, Anastas Batalov, Tanya Deneva, Nonka Mateva, Zlatimir Kolarov, Victoria Sarafian.   

Abstract

YKL-40, also known as human cartilage glycoprotein 39, is a member of the "mammalian chitinase-like proteins" family without chitinase activity. Increased serum concentrations are associated with inflammatory processes and several types of cancer. In this study, we evaluated YKL-40 levels in serum and synovial fluid of patients with rheumatoid arthritis in comparison with the ultrasonographic findings. YKL-40 levels were measured by enzyme-linked immunosorbent assay in 25 patients with active rheumatoid arthritis and in 40 healthy subjects. B mode and power Doppler were performed to determine synovial thickening and vascularization. Serum YKL-40 level in patients was significantly higher than the concentration in healthy controls (P < 0.01). In patients with rheumatoid arthritis, the level of the glycoprotein in synovial fluid was remarkably elevated compared to the serum level (P = 0.003). The B mode and power Doppler scores correlated to YKL-40 in serum and synovial fluid (P = 0.07). Serum YKL-40 levels were related positively to serum markers of inflammation such as C-reactive protein (P = 0.004) and erythrocyte sedimentation rate (P = 0.003). This study is the first to demonstrate a relationship between YKL-40 levels and ultrasonographic examinations in Bulgarian patients with rheumatoid arthritis. The findings suggest that YKL-40 might be implicated in the pathogenesis of the disease and could indicate the level of joint inflammation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22451025     DOI: 10.1007/s00296-012-2387-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  32 in total

1.  Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology.

Authors:  B Volck; J S Johansen; M Stoltenberg; C Garbarsch ; P A Price; M Ostergaard; K Ostergaard; P Løvgreen-Nielsen; S Sonne-Holm; I Lorenzen
Journal:  Osteoarthritis Cartilage       Date:  2001-04       Impact factor: 6.576

2.  The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography.

Authors:  R J Wakefield; W W Gibbon; P G Conaghan; P O'Connor; D McGonagle; C Pease; M J Green; D J Veale; J D Isaacs; P Emery
Journal:  Arthritis Rheum       Date:  2000-12

3.  Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity.

Authors:  R Peltomaa; L Paimela; S Harvey; T Helve; M Leirisalo-Repo
Journal:  Rheumatol Int       Date:  2001-07       Impact factor: 2.631

4.  Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation.

Authors:  M Rehli; S W Krause; R Andreesen
Journal:  Genomics       Date:  1997-07-15       Impact factor: 5.736

5.  Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma.

Authors:  Ralph A Francescone; Steve Scully; Michael Faibish; Sherry L Taylor; Dennis Oh; Luis Moral; Wei Yan; Brooke Bentley; Rong Shao
Journal:  J Biol Chem       Date:  2011-03-08       Impact factor: 5.157

6.  A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid.

Authors:  J S Johansen; H S Jensen; P A Price
Journal:  Br J Rheumatol       Date:  1993-11

7.  YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils.

Authors:  B Volck; P A Price; J S Johansen; O Sørensen; T L Benfield; H J Nielsen; J Calafat; N Borregaard
Journal:  Proc Assoc Am Physicians       Date:  1998 Jul-Aug

8.  YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation.

Authors:  Anne Roslind; Julia S Johansen
Journal:  Methods Mol Biol       Date:  2009

9.  YKL-40 tissue expression and plasma levels in patients with ovarian cancer.

Authors:  Estrid V S Høgdall; Merete Ringsholt; Claus K Høgdall; Ib Jarle Christensen; Julia S Johansen; Susanne K Kjaer; Jan Blaakaer; Lene Ostenfeld-Møller; Paul A Price; Lise H Christensen
Journal:  BMC Cancer       Date:  2009-01-09       Impact factor: 4.430

10.  Relationship between radiographic grading of osteoarthritis and the biochemical markers for arthritis in knee osteoarthritis.

Authors:  Masaaki Takahashi; Kenichi Naito; Masashi Abe; Tomokazu Sawada; Akira Nagano
Journal:  Arthritis Res Ther       Date:  2004-03-12       Impact factor: 5.156

View more
  15 in total

Review 1.  Inflammation in sleep apnea: an update.

Authors:  Dileep Unnikrishnan; Jonathan Jun; Vsevolod Polotsky
Journal:  Rev Endocr Metab Disord       Date:  2015-03       Impact factor: 6.514

Review 2.  The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review.

Authors:  Kalthoum Tizaoui; Jae Won Yang; Keum Hwa Lee; Ji Hong Kim; Minseok Kim; Sojung Yoon; Yeonwoo Jung; Joon Beom Park; Kitae An; Hyeok Choi; Donggyu Song; HyunTaek Jung; Seongmin Ahn; Taeho Yuh; Hee Min Choi; Jae Ha Ahn; Younjuong Kim; Sanghyun Jee; Hyeongsun Lee; Soohwa Jin; Jun-Gu Kang; Bohyun Koo; Joo Yeop Lee; Kyoung Min Min; Wonseok Yoo; Hyeong Jun Rhyu; Yeonjung Yoon; Min Ho Lee; Sung Eun Kim; Jimin Hwang; Ai Koyanagi; Louis Jacob; Seoyeon Park; Jae Il Shin; Lee Smith
Journal:  Int J Biol Sci       Date:  2022-05-21       Impact factor: 10.750

3.  Serum YKL-40 and IL-6 levels correlate with ultrasound findings of articular and periarticular involvement in patients with systemic sclerosis.

Authors:  Rositsa Karalilova; Maria Kazakova; Tanya Sapundzhieva; Valentin Dichev; Zguro Batalov; Victoria Sarafian; Anastas Batalov
Journal:  Rheumatol Int       Date:  2019-08-02       Impact factor: 2.631

4.  Adenovirus vector-mediated YKL-40 shRNA attenuates eosinophil airway inflammation in a murine asthmatic model.

Authors:  Ling Wang; Aihua Bao; Ying Zheng; Aying Ma; Yi Wu; Huanxia Shang; Danruo Fang; Suqin Ben
Journal:  Gene Ther       Date:  2020-10-12       Impact factor: 5.250

5.  Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality - a cohort study.

Authors:  Allan Klitgaard Sørensen; Dennis Back Holmgaard; Lone Hagens Mygind; Julia Johansen; Court Pedersen
Journal:  J Inflamm (Lond)       Date:  2015-03-18       Impact factor: 4.981

6.  Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.

Authors:  Tuija Väänänen; Katriina Vuolteenaho; Hannu Kautiainen; Riina Nieminen; Timo Möttönen; Pekka Hannonen; Markku Korpela; Markku J Kauppi; Kari Laiho; Oili Kaipiainen-Seppänen; Riitta Luosujärvi; Tea Uusitalo; Toini Uutela; Marjatta Leirisalo-Repo; Eeva Moilanen
Journal:  PLoS One       Date:  2017-08-25       Impact factor: 3.240

7.  Chitinase-3-like protein 1 (YKL-40) is a biomarker of severity of joint involvement in psoriatic arthritis.

Authors:  Joanna Salomon; Łukasz Matusiak; Danuta Nowicka-Suszko; Jacek C Szepietowski
Journal:  Postepy Dermatol Alergol       Date:  2018-07-19       Impact factor: 1.837

8.  Comment on "The Role of Citrullinated Protein Antibodies in Predicting Erosive Disease in Rheumatoid Arthritis: A Systematic Literature Review and Meta-Analysis".

Authors:  Shailendra Kapoor
Journal:  Int J Rheumatol       Date:  2015-08-23

9.  High CHI3L1 expression is associated with glioma patient survival.

Authors:  Giedrius Steponaitis; Daina Skiriutė; Arunas Kazlauskas; Ieva Golubickaitė; Rytis Stakaitis; Arimantas Tamašauskas; Paulina Vaitkienė
Journal:  Diagn Pathol       Date:  2016-04-27       Impact factor: 2.644

10.  Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma.

Authors:  Ying-Cheng Chiang; Han-Wei Lin; Chi-Fang Chang; Ming-Cheng Chang; Chi-Feng Fu; Tsung-Ching Chen; Shu-Feng Hsieh; Chi-An Chen; Wen-Fang Cheng
Journal:  Oncotarget       Date:  2015-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.